Lyra Therapeutics Inc

Company Profile

Lyra Therapeutics Inc had its IPO on 2020-05-01 under the ticker symbol LYRA.

The company operates in the LIFE SCIENCES sector and SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry. Lyra Therapeutics Inc has a staff strength of 0 employees.

Stock update

Shares of Lyra Therapeutics Inc opened at $4.8 at the start of the last trading session i.e. 2022-11-02.

The stocks traded within a range of $4.61 - $4.8, and closed at $4.72.

This is a +0.64% increase from the previous day's closing price.

A total volume of 7,317 shares were traded at the close of the day’s session.

In the last one week, shares of Lyra Therapeutics Inc have slipped by -5.6%.

Lyra Therapeutics Inc's Key Ratios

Lyra Therapeutics Inc has a market cap of $0.150 billion, indicating a price to book ratio of 1.364 and a price to sales ratio of 24.79.

In the last 12-months Lyra Therapeutics Inc’s revenue was $0.006 billion with a gross profit of $-0.029 billion and an EBITDA of $-0.045 billion. The EBITDA ratio measures Lyra Therapeutics Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Lyra Therapeutics Inc’s operating margin was -764% while its return on assets stood at -28% with a return of equity of -54.8%.

In Q2, Lyra Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.

Lyra Therapeutics Inc’s PE and PEG Ratio

Forward PE

-

Trailing PE

-

PEG

None

Its diluted EPS in the last 12-months stands at $-3.286 per share while it has a forward price to earnings multiple of - and a PEG multiple of None. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Lyra Therapeutics Inc’s profitability.

Lyra Therapeutics Inc stock is trading at a EV to sales ratio of 5.24 and a EV to EBITDA ratio of -0.705. Its price to sales ratio in the trailing 12-months stood at 24.79.

Lyra Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$0.000 billion

Total Liabilities

$0.000 billion

Operating Cash Flow

$0.000 billion

Capital Expenditure

$0.000 billion

Dividend Payout Ratio

0%

Lyra Therapeutics Inc ended 1970 with $0.000 billion in total assets and $131.2 billion in total liabilities. Its intangible assets were valued at $0.000 billion while shareholder equity stood at $0.000 billion.

Lyra Therapeutics Inc ended 1970 with $0.000 billion in deferred long-term liabilities, $0.000 billion in other current liabilities, billion in common stock, $0.000 billion in retained earnings and $0.000 billion in goodwill. Its cash balance stood at $0.000 billion and cash and short-term investments were $0.000 billion. The company’s total short-term debt was $0.000 billion while long-term debt stood at $0.000 billion.

Lyra Therapeutics Inc’s total current assets stands at $0.000 billion while long-term investments were $0.000 billion and short-term investments were $0.000 million. Its net receivables were $0.000 billion compared to accounts payable of $0.000 billion and inventory worth $0.000 billion.

In 1970, Lyra Therapeutics Inc's operating cash flow was $0.000 billion while its capital expenditure stood at $0.000 billion.

Comparatively, Lyra Therapeutics Inc paid $0 billion in dividends in 1970.

Other key metrics

Current Trading Price

$4.72

52-Week High

$8.18

52-Week Low

$3.3

Analyst Target Price

$17.75

Lyra Therapeutics Inc stock is currently trading at $4.72 per share. It touched a 52-week high of $8.18 and a 52-week low of $8.18. Analysts tracking the stock have a 12-month average target price of $17.75.

Its 50-day moving average was $0 and 200-day moving average was $0 The short ratio stood at indicating a short percent outstanding of 0%.

Around 0% of the company’s stock are held by insiders while 0% are held by institutions.